226 related articles for article (PubMed ID: 29235613)
21. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
22. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
23. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma.
Bradt A; Jing X; Smola BS; Lew M
Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
Liu H; Shi J; Prichard JW; Gong Y; Lin F
Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
[TBL] [Abstract][Full Text] [Related]
25. Utility of GATA3, mammaglobin, GCDFP-15, and ER in the detection of intrathoracic metastatic breast carcinoma.
Dyhdalo KS; Booth CN; Brainard JA; Croyle MC; Kolosiwsky AM; Goyal A; Gildea TR; Almeida FA; Nassar A; Reynolds JP
J Am Soc Cytopathol; 2015; 4(4):218-224. PubMed ID: 31051757
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the utility of trefoil factor 1 as a mammary-specific immunostain compared and in conjunction with GATA-3 and mammaglobin in the distinction between carcinoma of breast and lung.
Wells JM; Ginter PS; Liu Y; Chen Z; Narula N; Shin SJ
Am J Clin Pathol; 2015 Sep; 144(3):444-51. PubMed ID: 26276775
[TBL] [Abstract][Full Text] [Related]
27. Markers of metastatic carcinoma of breast origin.
Gown AM; Fulton RS; Kandalaft PL
Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031
[TBL] [Abstract][Full Text] [Related]
28. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors.
Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y
Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583
[TBL] [Abstract][Full Text] [Related]
29. Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin.
Kanner WA; Galgano MT; Stoler MH; Mills SE; Atkins KA
Int J Gynecol Pathol; 2008 Oct; 27(4):491-5. PubMed ID: 18753974
[TBL] [Abstract][Full Text] [Related]
30. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors.
Wang LJ; Greaves WO; Sabo E; Noble L; Tavares R; Ng T; DeLellis RA; Resnick MB
Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):505-11. PubMed ID: 19620839
[TBL] [Abstract][Full Text] [Related]
31. Preferential expression of NY-BR-1 and GATA-3 in male breast cancer.
Biserni GB; Di Oto E; Moskovszky LE; Foschini MP; Varga Z
J Cancer Res Clin Oncol; 2018 Feb; 144(2):199-204. PubMed ID: 29116378
[TBL] [Abstract][Full Text] [Related]
32. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
33. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y
Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280
[TBL] [Abstract][Full Text] [Related]
34. Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens.
Fiel MI; Cernaianu G; Burstein DE; Batheja N
Acta Cytol; 1996; 40(4):637-41. PubMed ID: 8693878
[TBL] [Abstract][Full Text] [Related]
35. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas.
Yang M; Nonaka D
Mod Pathol; 2010 May; 23(5):654-61. PubMed ID: 20173733
[TBL] [Abstract][Full Text] [Related]
36. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
[TBL] [Abstract][Full Text] [Related]
37. Solid neuroendocrine carcinomas of the breast: metastases or primary tumors?
Richter-Ehrenstein C; Arndt J; Buckendahl AC; Eucker J; Weichert W; Kasajima A; Schneider A; Noske A
Breast Cancer Res Treat; 2010 Nov; 124(2):413-7. PubMed ID: 20872069
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous and mammary apocrine carcinomas have different immunoprofiles.
Piris A; Peng Y; Boussahmain C; Essary LR; Gudewicz TM; Hoang MP
Hum Pathol; 2014 Feb; 45(2):320-6. PubMed ID: 24342430
[TBL] [Abstract][Full Text] [Related]
39. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P
Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362
[TBL] [Abstract][Full Text] [Related]
40. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases.
Boto A; Harigopal M
Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]